CCL2 and neoplasm: Taken together, these data suggest that MOv18 IgE may support TAM populations with mature phenotypes and hybrid M1/M2 features that are able to enter the tumour, trigger sustained immune activating pathways and secretion of IL-10, TNFα, MCP-1 and IL-1α in tumour-bearing lungs.